New cocktail of four drugs targets tough sarcomas in kids
NCT ID NCT07444619
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests a combination of four drugs—pazopanib, trabectedin, ipilimumab, and nivolumab—in children and young adults up to age 30 whose soft tissue sarcomas have come back. The goal is to see if adding pazopanib to the existing three-drug regimen is safe and helps control the cancer. Only 18 participants will be enrolled at M.D. Anderson Cancer Center.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pazopanib, trabectedin, ipilimumab, and nivolumab
What this could lead to
If successful, this could lead to a new combination therapy that helps control recurrent soft tissue sarcomas in young patients.
What could go wrong
This is a very early Phase 1 trial with only 18 participants, so safety and effectiveness are not yet known. The drug combination may cause serious side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOFT TISSUE SARCOMAS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The University of Texas M. D. Anderson Cancer Center
Houston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact